PerspectiveImmunotherapy

ICOStomizing Immunotherapies with TH17

See allHide authors and affiliations

Science Translational Medicine  27 Oct 2010:
Vol. 2, Issue 55, pp. 55ps52
DOI: 10.1126/scitranslmed.3001722

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

New insights on the role of costimulatory molecules in T helper cell function have yielded exciting alternatives to the development of therapeutic strategies that target T cell costimulatory pathways. Inducible costimulatory molecule (ICOS) signaling is now shown by Paulos and colleagues to support expansion of human T helper 17 (TH17) cells that could exert antitumor activity. Here we discuss (i) how these findings aid in our understanding of mechanisms that govern TH17 cell functions and (ii) the potential application of these new insights to the development of immunotherapies.

Footnotes

  • Citation: J. Garaude, J. M. Blander, ICOStomizing immunotherapies with TH17. Sci. Transl. Med. 2, 55ps52 (2010).

View Full Text